AACR Associate Member Council members offer advice for how graduate students can make the most of AACR resources for...
The flurry of decisions from the U.S. Food and Drug Administration (FDA) on investigational anticancer therapeutics continued last week...
Last week, the U.S. Food and Drug Administration (FDA) provided some good news for the lung cancer community during...
Last week, the U.S. Food and Drug Administration (FDA) approved the use of cobimetinib (Cotellic) in combination with vemurafenib...
The AACR’s disparities conference covered a wide array of issues this year, from the biological factors that make some...
Raymond DuBois, MD, PhD, past-president of the AACR (2008-2009), fellow of the AACR Academy, and chairman and president of...
Guest post by L. Michelle Bennett, director of the NCI Center for Research Strategies; Worta McCaskill-Stevens, MD, chief of...
The flurry of anticancer therapeutics approved by the U.S. Food and Drug Administration (FDA) late last month included the...
Kimberly Stegmaier, MD, co-director of the pediatric hematologic malignancy program and associate professor of pediatrics at Dana-Farber Cancer Institute...
Guest Post by Charles L. Sawyers, MD AACR Project GENIE Steering Committee Chairperson
Levi Garraway, MD, PhD, co-chair of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston Nov....